592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Authors :: U.A. Matulonis
K.N. Moore
D. Lorusso
A. Oaknin
S. Pignata
H. Denys
N. Colombo
T. Van Gorp
J. Konner
M. Romeo Marin
P. Harter
C. Murphy
Y. Tu
F. Zhu
B. Esteves
M. Method
M.J. Birrer
R.L. Coleman
D. O'Malley
Source :: Annals of Oncology. 33:S817
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools